BioCentury
ARTICLE | Company News

Forma achieves milestones in Celgene, Boehringer deals

June 18, 2015 12:56 AM UTC

Forma Therapeutics Inc. (Watertown, Mass.) received undisclosed milestone payments from Celgene Corp. (NASDAQ:CELG) and Boehringer Ingelheim GmbH (Ingelheim, Germany) under two separate development deals.

One milestone was triggered after Celgene obtained an exclusive EU license for an undisclosed epigenetics program. Forma expects to begin Phase I trials next half; Celgene will be responsible for development after Phase I. Under their 2014 deal, the partners are discovering and developing compounds targeting undisclosed protein families across a range of therapeutic areas (see BioCentury Extra, April 1, 2014). ...